Treats anemia. Sold as Aranesp. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Darbepoetin Alfa (sold as Aranesp), first approved Sep 17, 2001, with 7 new uses approved and 0 published complete response letters.
| Combination Therapy of Romiplostim and Erythropoiesis-stimulating AgentsAnemia Associated With Chronic Kidney Disease · Chinese University of Hong Kong | Phase 2 | Recruiting | Oct 2, 2026 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite AthletesSafety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes · Enhanced Emirates Limited | Not applicable | Enrolling by invitation | May 6, 2026 |
| Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis PatientsRenal Anemia · Mackay Memorial Hospital | Phase 4 | Not yet recruiting | Apr 17, 2026 |
| Anemia Therapy in Patients With Infective EndocarditisInfective Endocarditis (IE), Severe Anemia · Copenhagen University Hospital, Rigshospitalet | Phase 4 | Recruiting | Apr 13, 2026 |
| A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)Anaemia · Qilu Pharmaceutical Co., Ltd. | Phase 3 | Not yet recruiting | Dec 23, 2025 |
| Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)Liver Transplant; Complications · Fundacion Clinic per a la Recerca Biomédica | Phase 3 | Recruiting | Sep 12, 2025 |
| National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated CirrhosisDecompensated Cirrhosis · Institute of Liver and Biliary Sciences, India | Not applicable | Not yet recruiting | Aug 20, 2025 |
| Project CARE: CAncer Risk EvaluationPrimary Care · Anita Y. Kinney, PhD, RN | Not applicable | Recruiting | Aug 19, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Amgen